See attached
Unit II DB GSM
Your initial post should be at least 300 words in length. Your initial post should include at least one APA-formatted scholarly, professional, or textbook reference with accompanying in-text citation to support any paraphrased, summarized, or quoted material.
Select a firm with global operations. Provide a brief corporate profile of the firm and highlight two key points from its global strategy. How has technology changed global corporate strategy models? What are the strengths and weaknesses of this firm? Discuss perceptions of the firm (reviews, discussions in forums or social media, news reports, and your reflection/experiences)
Please note you will use the firm selected for this discussion to develop a course paper to be submitted in Unit VII of the course.
Reply 1: Nathaniel Mainville
BorgWarner Inc. is a U.S.-based automotive and emobility supplier headquartered in Auburn Hills, Michigan. The company is a major global player, operating 92 locations across 24 countries, illustrating its substantial international footprint in the automotive supply chain. Its product portfolio includes air management systems, drivetrain technologies, turbocharging systems, and electric propulsion components, core technologies supporting the automotive industry’s ongoing transition toward electrification.
Two key elements of BorgWarner’s global strategy are especially noteworthy. First, the company leverages a globally distributed production and engineering network, allowing it to locate operations near major automaker hubs around the world and reduce logistical risks while maintaining responsiveness to regional regulatory and market conditions. Second, BorgWarner continues expanding its commitment to emobility innovation, aligning with broader industry shifts toward electric and hybrid propulsion. These strategic directions are consistent with industry-wide insights identified by the Boston Consulting Group, which emphasizes that global suppliers must invest heavily in electrification technologies and operational resilience to remain competitive in a rapidly evolving automotive landscape (BCG, 2025).
Technology has significantly reshaped global corporate strategy models. Digital engineering platforms, realtime supply chain analytics, and automation technologies enable BorgWarner to coordinate crossborder operations more efficiently than ever. These advancements support more agile strategic decisionmaking, reduce operational bottlenecks, and improve collaboration across continents, demonstrating how technological evolution has transformed global strategy from a longterm static model into a dynamic, adaptive framework.
BorgWarner’s strengths include its global presence, diversified product range, and strong positioning within the electrification movement. Its weaknesses stem partly from exposure to cyclical automotive markets and the capitalintensive nature of keeping pace with EV technology development. Public perception of BorgWarner remains generally positive, with industry news often highlighting the firm’s EVrelated innovations. Forum discussions and industry commentary tend to view BorgWarner as a stable and forwardthinking supplier, though concerns occasionally arise regarding broader industry volatility and competitive pressures. From my perspective, BorgWarner stands out as an adaptable, globally integrated supplier that has strategically aligned itself with the future trajectory of automotive technology.
Reference
Boston Consulting Group. (2025).
Automotive suppliers at the crossroads: Insights from BCG’s 2025 automotive supplier industry report. [media-publ…ns.bcg.com]
Reply 2 Arielle Dennis
Pfizer Inc. is a U.S.-based multinational pharmaceutical corporation founded in 1849, with operations spanning more than 125 countries. The company focuses on the research, development, manufacturing, and commercialization of innovative medicines and vaccines across multiple therapeutic areas, including oncology, immunology, and infectious diseases (Pfizer, n.d.). Pfizer’s global footprint and R&D intensity position it as a leading example of a firm competing under a global integration strategy, as described by Rothaermel (2023).
Two key elements define Pfizer’s global strategy. First, Pfizer emphasizes strategic alliances and partnerships to accelerate innovation and market access. The collaboration with BioNTech to develop and distribute the COVID-19 mRNA vaccine exemplifies this approach, allowing Pfizer to rapidly scale manufacturing and global distribution while sharing technological expertise. Second, Pfizer leverages global economies of scale in manufacturing and supply chain management. During the COVID-19 pandemic, this capability enabled rapid worldwide deployment of vaccines, reinforcing Pfizer’s competitive advantage in speed and reach.
Technology has significantly reshaped global corporate strategy models, particularly in the pharmaceutical industry (Rothaermel, 2023). Advances in biotechnology, digital collaboration platforms, and data analytics have reduced innovation cycles and enabled firms like Pfizer to coordinate R&D, clinical trials, and regulatory submissions across borders more efficiently. Pfizer’s investment in mRNA technology and digitally integrated global manufacturing and distribution networks illustrates how firm-specific technological capabilities can be leveraged to reshape industry standards and strengthen global competitive positioning (Pfizer, n.d.).
Pfizer’s strengths include its strong R&D pipeline, global brand recognition, robust financial resources, and proven ability to navigate complex regulatory environments. However, the firm also faces weaknesses, including public skepticism toward large pharmaceutical companies, dependence on blockbuster products, and exposure to patent expirations. Public perception of Pfizer became especially polarized during the COVID-19 pandemic. While many view the company as a scientific leader responsible for life-saving innovation, social media analyses reveal skepticism and misinformation surrounding vaccine safety, particularly on platforms such as TikTok (Baumel et al., 2022).
References
Baumel, N. M., Spatharakis, J. K., Baumel, L. D., & Sellas, E. I. (2022). Disparity in public perception of Pfizer and Moderna COVID-19 vaccines on TikTok.
Journal of Adolescent Health, 70(3), 514.
Rothaermel, F. T. (2023).
Strategic management (6th ed.). McGraw-Hill Higher Education.
